S100A8/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure

  • Nat Commun. 2024 Mar 27;15(1):2701. doi: 10.1038/s41467-024-46973-7.
Jie Ma  #  1  2 ,  Yang Li  #  1  2 ,  Ping Li  #  1 ,  Xinying Yang  1  2 ,  Shuolin Zhu  1  2 ,  Ke Ma  1  2 ,  Fei Gao  1 ,  Hai Gao  1 ,  Hui Zhang  3 ,  Xin-Liang Ma  4 ,  Jie Du  1  2 ,  Yulin Li  5  6
Affiliations
  • 1. Beijing Anzhen Hospital of Capital Medical University, Beijing, China.
  • 2. Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
  • 3. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • 4. Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
  • 5. Beijing Anzhen Hospital of Capital Medical University, Beijing, China. [email protected].
  • 6. Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China. [email protected].
  • # Contributed equally.
PMID: 38538601 DOI: 10.1038/s41467-024-46973-7
Abstract

Heart Failure is the prevalent complication of acute Myocardial Infarction. We aim to identify a biomarker for Heart Failure post-acute Myocardial Infarction. This observational study includes 1062 and 1043 patients with acute Myocardial Infarction in the discovery and validation cohorts, respectively. The outcomes are in-hospital and long-term Heart Failure events. S100A8/A9 is screened out through proteomic analysis, and elevated circulating S100A8/A9 is independently associated with Heart Failure in discovery and validation cohorts. Furthermore, the predictive value of S100A8/A9 is superior to the traditional biomarkers, and the addition of S100A8/A9 improves the risk estimation using traditional risk factors. We finally report causal effect of S100A8/A9 on Heart Failure in three independent cohorts using Mendelian randomization approach. Here, we show that S100A8/A9 is a predictor and potentially causal medicator for Heart Failure post-acute Myocardial Infarction.